British Journal of Clinical Pharmacology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Pharmacogenetics of artemether ‐lumefantrine influence on nevirapine disposition: clinically significant drug‐drug interaction?
ConclusionsThis approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolisers when nevirapine is co ‐administered with artemether‐lumefantrine. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 24, 2018 Category: Drugs & Pharmacology Authors: Sa ’ad T. Abdullahi,
Adeniyi Olagunju,
Julius O. Soyinka,
Rahman A. Bolarinwa,
Olusola J. Olarewaju,
Moji T. Bakare‐Odunola,
Andrew Owen,
Saye Khoo Tags: ORIGINAL ARTICLE Source Type: research
Update on pharmacologically ‐relevant vitamin D analogues
Pharmacologists have been interested in vitamin D since its metabolism was elucidated in the early 1970s. Despite the synthesis of thousands of vitamin D analogues in the hope of separating its calcemic and anti ‐proliferative properties, few molecules have reached the market for use in the treatment of clinical conditions from psoriasis to chronic kidney disease. This review discusses vitamin D drugs, recently developed or still under development, for use in various diseases, but in particular bone disea se. In the process we explore the mechanisms postulated to explain the action of these vitamin D analogues including ...
Source: British Journal of Clinical Pharmacology - November 22, 2018 Category: Drugs & Pharmacology Authors: Glenville Jones,
Martin Kaufmann Tags: REVIEW ‐THEMED ISSUE Source Type: research
Integrating anatomo ‐physiological changes and pharmacogenomics in anti‐infective therapy management: is it a major concern?
Success of anti ‐infective therapy is a major challenge in some patients given anatomo‐physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Laura Beaumier,
S ébastien Chanoine,
Elodie Gautier‐Veyret,
Hélène Pluchart,
Muriel Cornet,
Marie‐Pierre Brenier‐Pinchart,
Xavier Fonrose,
Boubou Camara,
Pierrick Bedouch Tags: CASE REPORT Source Type: research
Plasma extracellular nanovesicle (exosome) ‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure
ConclusionsConsistent strong concordance was observed between exosome ‐derived CYP3A4 biomarkers and midazolam CL/F. The significance of these results is that CYP3A4 is the drug‐metabolizing enzyme of greatest clinical importance and variability in CYP3A4 activity is poorly described by existing precision dosing strategies. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Andrew Rowland,
Warit Ruanglertboon,
Madel é Dyk,
Dhilushi Wijayakumara,
Linda S. Wood,
Robyn Meech,
Peter I. Mackenzie,
A. David Rodrigues,
Jean‐Claude Marshall,
Michael J. Sorich Tags: ORIGINAL ARTICLE Source Type: research
Integrating anatomo ‐physiological changes and pharmacogenomics in anti‐infective therapy management: is it a major concern?
Success of anti ‐infective therapy is a major challenge in some patients given anatomo‐physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Laura Beaumier,
S ébastien Chanoine,
Elodie Gautier‐Veyret,
Hélène Pluchart,
Muriel Cornet,
Marie‐Pierre Brenier‐Pinchart,
Xavier Fonrose,
Boubou Camara,
Pierrick Bedouch Tags: CASE REPORT Source Type: research
Plasma extracellular nanovesicle (exosome) ‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure
ConclusionsConsistent strong concordance was observed between exosome ‐derived CYP3A4 biomarkers and midazolam CL/F. The significance of these results is that CYP3A4 is the drug‐metabolizing enzyme of greatest clinical importance and variability in CYP3A4 activity is poorly described by existing precision dosing strategies. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 16, 2018 Category: Drugs & Pharmacology Authors: Andrew Rowland,
Warit Ruanglertboon,
Madel é Dyk,
Dhilushi Wijayakumara,
Linda S. Wood,
Robyn Meech,
Peter I. Mackenzie,
A. David Rodrigues,
Jean‐Claude Marshall,
Michael J. Sorich Tags: ORIGINAL ARTICLE Source Type: research
Physiologically ‐based pharmacokinetic modelling to predict oprozomib CYP3A drug‐drug interaction potential in patients with advanced malignancies
ConclusionsThese results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans. The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds. Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 14, 2018 Category: Drugs & Pharmacology Authors: Ying Ou,
Yang Xu,
Lia Gore,
R. Donald Harvey,
Alain Mita,
Kyriakos P. Papadopoulos,
Zhengping Wang,
Richard E. Cutler,
Dawn E. Pinchasik,
Apostolia M. Tsimberidou Tags: ORIGINAL ARTICLE Source Type: research
Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin,
Caroline Dureau ‐Pournin,
Yves Cottin,
Jacques Bénichou,
Patrick Mismetti,
Abdelilah Abouelfath,
Regis Lassalle,
Cécile Droz,
Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller,
Samantha Alvarez ‐Madrazo,
Chris Robertson,
Olivia Wu,
Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research
Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin,
Caroline Dureau ‐Pournin,
Yves Cottin,
Jacques Bénichou,
Patrick Mismetti,
Abdelilah Abouelfath,
Regis Lassalle,
Cécile Droz,
Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller,
Samantha Alvarez ‐Madrazo,
Chris Robertson,
Olivia Wu,
Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research
Reply to ‘Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018’ by Weibel et al.
British Journal of Clinical Pharmacology, EarlyView. (Source: British Journal of Clinical Pharmacology)
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Vanessa Pauly,
Elisabeth Frauger,
Marion Lepelley,
Michel Mallaret,
Quentin Boucherie,
Joelle Micallef Tags: LETTER TO THE EDITOR Source Type: research
Prolonged central apnoea after intravenous morphine administration in a 12 ‐year‐old male with a UGT1A1 loss‐of‐function polymorphism
Adverse eventRepeated and prolonged episodes of central apnoea and hypoxia after receiving intravenous morphine for analgesia and ketamine for sedation.Drug implicatedIntravenous morphine sulfate.The patientPreviously healthy 12 ‐year‐old male with no history of sleep apnoea who presented with distal tibia and fibula fracture.Evidence that links drug to eventPharmacogenomic testing revealed that the patient was homozygous for the T allele at the rs887829 SNP inUGT1A1, an enzyme involved in the metabolism of morphine. This polymorphism is a loss ‐of‐function variant, leading to impaired metabolism of morphine.Mechan...
Source: British Journal of Clinical Pharmacology - November 12, 2018 Category: Drugs & Pharmacology Authors: Michael S. Toce,
Hyun Kim,
Sarita Chung,
Baruch S. Krauss Tags: CASE REPORT Source Type: research
